A randomized trial of short psychotherapy versus sustained‐release bupropion for smoking cessation

Zernig, Gerald; Wallner, Reinhild; Grohs, Ursula; Kriechbaum, Norbert; Kemmler, Georg; Saria, Alois

doi:10.1111/j.1360-0443.2008.02348.x

Cited by 36 publications

(28 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To effectively cope with PADed superiors, various techniques from a host of psychotherapeutic approaches (see, e.g., [44,45,46]) may be introduced to and trained with a PAD victim. It is to be expected that a PADed superior will not seek help during most of her/his disease progression (see above and below).…”

Section: Treating Padmentioning

confidence: 99%

Making the Case for ‘Power Abuse Disorder' as a Nosologic Entity

Zernig

Hiemke²

2017

Pharmacology

Self Cite

View full text Add to dashboard Cite

The development of societies and cultures arguably is based on the ability of human primates to form hierarchies in which some individuals acquire and wield power, that is, control resources and influence and control the behavior of their conspecifics. In the following, we focus on the type of human primate power wielding that (a) harms and (b) produces excessive negative emotions in (1) the victim(s) of the power wielder and (2) the power wielder her/himself. If such a harmful behavior of the power wielder is not accompanied by an ethically justifiable benefit for the involved human primate groups, it can be considered “power abuse.” We propose to term the associated behaviors, cognitions, and emotions of the power wielder as “power abuse disorder” (PAD). This behavior results from what we consider addictive behavior of the power abuse disordered (PADed) power wielder. PAD can be diagnosed on the basis of the World Health Organization's criteria for “dependence syndrome” as listed in the International Classification of Diseases version 10. We will demonstrate that many PADed individuals may very likely carry the Zeitgeist diagnosis “burnout.” This article reviews the current understanding of the neural correlates of PAD and suggests future research. Based on the available evidence, PAD seems to be associated with a dysfunction of the mesocorticolimbic dopamine system, rendering PADed individuals vulnerable for psychostimulant abuse/dependence, and suggesting specific pharmacotherapeutic approaches to treat PAD.

show abstract

Section: Treating Padmentioning

confidence: 99%

Making the Case for ‘Power Abuse Disorder' as a Nosologic Entity

Zernig

Hiemke²

2017

Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…With respect to the alleged uniqueness of our 3-month results, we re-emphasize that continuous abstinence was defined strictly according to the Russell Standard as detailed by West and colleagues [3] and that in that very same paper, 'point prevalence' is repeatedly defined as 'at the time of the follow-up', i.e., without giving any specified observation period [3]. In our trial, subjects were first contacted by telephone and asked about their smoking status.…”

Section: Replication and Further Scientific Investigations Will Tell mentioning

confidence: 85%

“…The article by Zernig et al [3] reports that a 1.5-day session of Psychodynamic Model Training (PDM) appears to have achieved validated continuous success rates of a magnitude without parallel in the world literature, and that the psychotherapy treatment was more than three times more effective than bupropion, a smoking cessation medication with strong evidence of efficacy [4].…”

mentioning

confidence: 99%

[Commentary] IS THIS A BREAKTHROUGH IN PSYCHOLOGICAL TREATMENT OF ADDICTION, OR ARE MOMMY AND I ONE AGAIN?

HAJEK

2008

Addiction

View full text Add to dashboard Cite

“…From the psychotherapeutic perspective, this overreporting of abstinence is very plausible because failure to remain abstinent, i.e. failure to reach the explicit goal of the therapeutic intervention, is often perceived as shameful by the participant, constituting a threat to his/ her self-worth [12,17,18] .…”

Section: Sensitivities Of Uc and Breath Co In Smoking Cessation Trialsmentioning

confidence: 99%

“…training to use recorded guided imagery for autosuggestion), to a medication, sustained-release bupropion (Zyban ; administered over 9 weeks as recommended by the manufacturer), as smoking cessation aids [12] . Details of the study design, the participant flow, participants' demographics and the outcome have been presented elsewhere [12] . Briefly, 779 participants, i.e.…”

Section: Study Design and Participantsmentioning

confidence: 99%

Comparable Sensitivities of Urine Cotinine and Breath Carbon Monoxide at Follow-Up Time Points of Three Months or More in a Smoking Cessation Trial

Fritz

Wallner²,

Grohs³

et al. 2010

Pharmacology

Self Cite

View full text Add to dashboard Cite

To control for likely overreporting of abstinence in clinical trials of smoking cessation aids, field convention demands the corroboration of subjects’ self-reports by a biochemical/pharmacological marker. It is, however, currently debated if urinary cotinine (UC), a metabolite of nicotine, should be preferred because of its higher sensitivity, although sample collection for and analysis of cotinine are much more expensive and work intensive than carbon monoxide (CO) measurements in exhaled air. In the present study, it turned out that UC was of only moderately higher sensitivity than CO (99.4% vs. 96.3%; p = 0.02), the difference being significant only at group sizes of >164. UC identified participants as smokers who escaped CO detection in 4.9% of the cases, whereas CO identified smokers who escaped UC detection in 2.7% of the cases (p = 0.014). Our findings suggest that the costs/disadvantages of using UC instead of CO may outweigh its benefit as a pharmacological marker of (non)smoking status.

show abstract

A randomized trial of short psychotherapy versus sustained‐release bupropion for smoking cessation

Abstract: The 1.5-day psychotherapy exceeded bupropion's efficacy, presenting an alternative to pharmacological smoking cessation aids, especially for smokers who reject drugs to treat their substance dependence, at a similar cost (Euro 350) as the bupropion treatment (Euro 355).

Cited by 36 publications

References 18 publications

Making the Case for ‘Power Abuse Disorder' as a Nosologic Entity

Making the Case for ‘Power Abuse Disorder' as a Nosologic Entity

[Commentary] IS THIS A BREAKTHROUGH IN PSYCHOLOGICAL TREATMENT OF ADDICTION, OR ARE MOMMY AND I ONE AGAIN?

Comparable Sensitivities of Urine Cotinine and Breath Carbon Monoxide at Follow-Up Time Points of Three Months or More in a Smoking Cessation Trial

Contact Info

Product

Resources

About